Notice: Undefined variable: fileR in
/me/beta.myiris.com/htdocs/newsCentre/bin/addLinksNew.php on line
17
Notice: Undefined variable: fileR in
/me/beta.myiris.com/htdocs/newsCentre/bin/addLinksNew.php on line
142
Heron Therapeutics, Inc (HRTX) saw its loss widen to $47.96 million, or $1.22 a share for the quarter ended Dec. 31, 2016. In the previous year period, the company reported a loss of $31.24 million, or $0.87 a share. Revenues for the quarter were $1.28 million. The company has not recorded any revenues for the previous year period. Gross margin for the quarter was at 97.26 percent.
Operating loss for the quarter was $46.80 million, compared with an operating loss of $31.06 million in the previous year period.
“2016 was an exciting and transformational year for Heron, highlighted by the release of our best-in-class Phase 2 data for HTX-011 and our FDA approval and commercial launch of SUSTOL,” said Barry D. Quart, Pharm.D., Chief Executive Officer of Heron. “2017 is off to a promising start as well, highlighted by our submission of an NDA for CINVANTI, our second, complementary therapeutic agent in the CINV category, and the release of strong Phase 2 results of HTX-011 in abdominoplasty.”
Disclaimer: Please note that this is an auto-generated article. IRIS does not guarantee the accuracy, adequacy or completeness of any information and is not responsible for any errors or omissions or for the results obtained from the use of such information. IRIS especially states that it has no financial liability whatsoever to any user on account of the use of information provided on its website. For queries contact: editor@irisindia.net
